Archives20242023202220212020201920182017201620152014201320122011 April 30, 2015Preliminary Results Announcement for the year ended 31 December 2014 Read More April 30, 2015Dr Stéphane Méry Appointed as Non-Executive Director Read More February 11, 2015Cancer Update: IPP-204106 Read More January 27, 2015Advance Assurance Received from H M Revenue and Customs Regarding “Enterprise Investment Scheme” Status Read More January 22, 2015Landmark Collaboration Agreement & Commencement of Pivotal Phase III Lupuzor™ Study with Simbec-Orion Read More October 21, 2014ImmuPharma awarded €400,000 grant in support of its pioneering research in the Bordeaux region of France Read More October 21, 2014AVIVA lead investor in £3.4 million fund raising to support Lupuzor™ Pivotal Phase III Progress Read More October 02, 2014INTERIM RESULTS ANNOUNCEMENT for the six months ended 30 June 2014 Read More October 02, 2014Lupuzor™ Gears Up To Start Pivotal Phase III trials Read More June 27, 2014ANNUAL GENERAL MEETING: 2014 Read More June 27, 2014ImmuPharma to access pioneering research in the Bordeaux region of France Read More June 16, 2014New Nucant Patents. New Optically Pure Compounds for Improved Therapeutic Efficiency Read More 1…1718192021
January 27, 2015Advance Assurance Received from H M Revenue and Customs Regarding “Enterprise Investment Scheme” Status Read More
January 22, 2015Landmark Collaboration Agreement & Commencement of Pivotal Phase III Lupuzor™ Study with Simbec-Orion Read More
October 21, 2014ImmuPharma awarded €400,000 grant in support of its pioneering research in the Bordeaux region of France Read More
October 21, 2014AVIVA lead investor in £3.4 million fund raising to support Lupuzor™ Pivotal Phase III Progress Read More
June 16, 2014New Nucant Patents. New Optically Pure Compounds for Improved Therapeutic Efficiency Read More